[go: up one dir, main page]

DK1001813T3 - Farmaceutiske formuleringer indeholdende voriconazol - Google Patents

Farmaceutiske formuleringer indeholdende voriconazol

Info

Publication number
DK1001813T3
DK1001813T3 DK98930793T DK98930793T DK1001813T3 DK 1001813 T3 DK1001813 T3 DK 1001813T3 DK 98930793 T DK98930793 T DK 98930793T DK 98930793 T DK98930793 T DK 98930793T DK 1001813 T3 DK1001813 T3 DK 1001813T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical formulations
formulations containing
containing voriconazole
voriconazole
pharmaceutical
Prior art date
Application number
DK98930793T
Other languages
Danish (da)
English (en)
Inventor
Valerie Denise Harding
Original Assignee
Pfizer
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10814734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1001813(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer, Pfizer Ltd filed Critical Pfizer
Application granted granted Critical
Publication of DK1001813T3 publication Critical patent/DK1001813T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK98930793T 1997-06-21 1998-06-02 Farmaceutiske formuleringer indeholdende voriconazol DK1001813T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9713149.4A GB9713149D0 (en) 1997-06-21 1997-06-21 Pharmaceutical formulations
PCT/EP1998/003477 WO1998058677A1 (fr) 1997-06-21 1998-06-02 Formulations pharmaceutiques contenant du voriconazole

Publications (1)

Publication Number Publication Date
DK1001813T3 true DK1001813T3 (da) 2003-07-28

Family

ID=10814734

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98930793T DK1001813T3 (da) 1997-06-21 1998-06-02 Farmaceutiske formuleringer indeholdende voriconazol

Country Status (47)

Country Link
US (1) US6632803B1 (fr)
EP (1) EP1001813B8 (fr)
JP (2) JP2000513029A (fr)
KR (1) KR100372988B1 (fr)
CN (1) CN1125653C (fr)
AP (1) AP912A (fr)
AR (1) AR015900A1 (fr)
AT (1) ATE238812T1 (fr)
AU (1) AU724799B2 (fr)
BG (1) BG64584B1 (fr)
BR (1) BRPI9809468B8 (fr)
CA (1) CA2295035C (fr)
CO (1) CO4940450A1 (fr)
CZ (1) CZ289570B6 (fr)
DE (1) DE69814091T2 (fr)
DK (1) DK1001813T3 (fr)
DZ (1) DZ2523A1 (fr)
EA (1) EA001924B1 (fr)
EG (1) EG23910A (fr)
ES (1) ES2195355T3 (fr)
GB (1) GB9713149D0 (fr)
HR (1) HRP980341B1 (fr)
HU (1) HU228338B1 (fr)
ID (1) ID22939A (fr)
IL (1) IL132918A (fr)
IS (1) IS2004B (fr)
MA (1) MA26508A1 (fr)
ME (1) ME00907B (fr)
MY (1) MY118151A (fr)
NO (1) NO313125B1 (fr)
NZ (1) NZ501066A (fr)
OA (1) OA11232A (fr)
PA (1) PA8453201A1 (fr)
PE (1) PE84899A1 (fr)
PL (1) PL191295B1 (fr)
PT (1) PT1001813E (fr)
RS (1) RS49633B (fr)
SA (1) SA98190159B1 (fr)
SI (1) SI1001813T1 (fr)
SK (1) SK282946B6 (fr)
TN (1) TNSN98090A1 (fr)
TR (1) TR199903191T2 (fr)
TW (1) TW406023B (fr)
UA (1) UA57083C2 (fr)
UY (1) UY25055A1 (fr)
WO (1) WO1998058677A1 (fr)
ZA (1) ZA985364B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818258D0 (en) * 1998-08-21 1998-10-14 Pfizer Ltd Antifungal compositions
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
DE60327225D1 (de) * 2002-08-20 2009-05-28 Bristol Myers Squibb Co Aripiprazol-komplex-formulierung und verfahren
GB0327390D0 (en) * 2003-11-25 2003-12-31 Pfizer Ltd Pharmaceutical formulations
CN1889943A (zh) * 2003-12-08 2007-01-03 美国亚利桑那大学董事会 协同抗癌组合物
EP1765336A4 (fr) 2004-06-25 2010-03-10 Univ Johns Hopkins Inhibiteurs d'angiogenese
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
US20070082870A1 (en) * 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
AR061889A1 (es) 2006-07-13 2008-10-01 Medichem Sa Proceso mejorado para la preparacion de voriconazol
CN1919846B (zh) * 2006-09-14 2013-01-02 大道隆达（北京）医药科技发展有限公司 伏立康唑及其药用盐、中间体的一种新定向合成制备方法
BG1110U1 (bg) * 2007-06-19 2008-09-30 Рудолф ПОДЛИПСКИ Отоплителен съд за експресно локално загряване навода
EP2018866A1 (fr) * 2007-07-27 2009-01-28 Sandoz AG Compositions pharmaceutiques contenant du voriconazole
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
US20110224232A1 (en) * 2008-05-06 2011-09-15 Board Of Regents, The University Of Texas System Treatment of Pulmonary Fungal Infection With Voriconazole via Inhalation
BRPI0914863A2 (pt) * 2008-06-06 2017-05-30 Glenmark Pharmaceuticals Ltd formulação tópica estável, e, uso da mesma
CN101390825B (zh) * 2008-10-01 2010-12-29 山东省眼科研究所 一种伏立康唑眼内释药系统
EP2349313A4 (fr) 2008-10-21 2012-08-29 Onyx Therapeutics Inc Thérapie de combinaison avec des peptides époxycétones
CN101444510B (zh) * 2008-12-31 2011-03-09 南京卡文迪许生物工程技术有限公司 含有伏立康唑的药物制剂及其制备方法
EP2467379B1 (fr) 2009-08-19 2016-03-02 ratiopharm GmbH Procédé pour la préparation des coévaporates et complexes comportant du voriconazole et cyclodextrine
WO2011064558A2 (fr) 2009-11-30 2011-06-03 Cipla Limited Composition pharmaceutique
MX338685B (es) 2010-06-29 2016-04-26 Merck Sharp & Dohme Formulaciones de solucion intravenosa de posaconacol estabilizadas mediante beta-ciclodextrina sustituida.
EP2409699B1 (fr) 2010-07-23 2014-04-30 Combino Pharm, S.L. Compositions stables de voriconazole
CN102058519B (zh) * 2010-11-19 2013-01-02 苏州特瑞药业有限公司 一种伏立康唑缓释栓剂及其制备方法
PL2720723T3 (pl) 2011-06-15 2018-10-31 Synthon Bv Stabilizowana kompozycja worykonazolu
EP2561863A1 (fr) 2011-08-22 2013-02-27 Farmaprojects, S.A.U. Compositions pharmaceutiques comportant du voriconazole
WO2013103925A2 (fr) * 2012-01-05 2013-07-11 Guilford Frederick Timothy Glutathione réduite encapsulée dans un liposome pour le traitement du cancer, autres utilisations et méthodes
US8853248B2 (en) 2012-04-05 2014-10-07 Hubert Maehr (1,2,3-triazolyl)sulfonyl derivatives
EP2662094B1 (fr) 2012-05-08 2024-04-17 Onyx Therapeutics, Inc. Procédés de complexation cyclodextrine pour formuler des inhibiteurs du protéasome de peptide
WO2013167865A1 (fr) 2012-05-11 2013-11-14 Cipla Limited Composition pharmaceutique
US20150352112A1 (en) 2013-01-11 2015-12-10 Xellia Pharmaceuticals Aps Voriconazole inclusion complexes
EP2968595A2 (fr) 2013-03-14 2016-01-20 Fresenius Kabi USA LLC Formulations de voriconazole
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
CN103690968A (zh) * 2013-11-21 2014-04-02 石药集团中奇制药技术（石家庄）有限公司 一种伏立康唑组合物及其制备方法
PT109117B (pt) * 2016-01-28 2019-02-01 Hovione Farm Sa Complexação de ingredientes ativos farmacêuticos
CA3043979A1 (fr) 2016-11-18 2018-05-24 Aicuris Anti-Infective Cures Gmbh Nouvelles formulations de composes de la famille des beta-lactamines substitues par une amidine, a base de cyclodextrines modifiees et d'agents acidifiants, leur preparation et leur utilisation en tant que compositions pharmaceutiques antimicrobiennes
WO2018149359A1 (fr) * 2017-02-17 2018-08-23 武汉朗来科技发展有限公司 Dérivé antibactérien de triazole, composition pharmaceutique et utilisation associées
CN113750034A (zh) * 2020-06-05 2021-12-07 中南大学湘雅三医院 耳用温敏凝胶及其制备方法
CN116570558B (zh) * 2023-06-21 2023-12-26 广州仁恒医药科技股份有限公司 一种伏立康唑眼用纳米缓释组合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
DE3347421A1 (de) 1983-12-29 1985-07-11 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von fluorarmen alkaliphosphatloesungen
GB8819308D0 (en) * 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9002375D0 (en) * 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
US5278175A (en) * 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
GB9512961D0 (en) 1995-06-26 1995-08-30 Pfizer Ltd Antifungal agents
GB9602080D0 (en) 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
ZA985364B (en) 1999-12-20
AP9801268A0 (en) 1998-06-30
CA2295035C (fr) 2005-04-19
HUP0003323A2 (hu) 2001-06-28
CZ409699A3 (cs) 2000-02-16
TR199903191T2 (xx) 2000-09-21
KR20010014006A (ko) 2001-02-26
EA199900937A1 (ru) 2000-08-28
JP2000513029A (ja) 2000-10-03
BG103882A (en) 2000-07-31
EP1001813A1 (fr) 2000-05-24
JP2002332234A (ja) 2002-11-22
NO995565D0 (no) 1999-11-12
BRPI9809468B8 (pt) 2022-01-18
UY25055A1 (es) 2000-12-29
CN1261287A (zh) 2000-07-26
UA57083C2 (uk) 2003-06-16
MA26508A1 (fr) 2004-12-20
RS49633B (sr) 2007-08-03
IL132918A0 (en) 2001-03-19
HRP980341B1 (en) 2001-12-31
EG23910A (en) 2007-12-30
DE69814091D1 (de) 2003-06-05
DZ2523A1 (fr) 2003-02-01
PT1001813E (pt) 2003-07-31
BG64584B1 (bg) 2005-08-31
DE69814091T2 (de) 2004-01-22
IL132918A (en) 2001-09-13
WO1998058677A1 (fr) 1998-12-30
HU228338B1 (en) 2013-03-28
TW406023B (en) 2000-09-21
EP1001813B1 (fr) 2003-05-02
PA8453201A1 (es) 2000-05-24
ID22939A (id) 1999-12-16
PL337692A1 (en) 2000-08-28
SK282946B6 (sk) 2003-01-09
CN1125653C (zh) 2003-10-29
PL191295B1 (pl) 2006-04-28
SI1001813T1 (en) 2004-02-29
BR9809468B1 (pt) 2013-11-12
EA001924B1 (ru) 2001-10-22
US6632803B1 (en) 2003-10-14
YU68199A (sh) 2002-06-19
HRP980341A2 (en) 1999-02-28
AR015900A1 (es) 2001-05-30
SK159399A3 (en) 2000-06-12
AU8110498A (en) 1999-01-04
HK1027966A1 (en) 2001-02-02
CZ289570B6 (cs) 2002-02-13
SA98190159B1 (ar) 2005-12-21
AU724799B2 (en) 2000-09-28
HUP0003323A3 (en) 2002-01-28
GB9713149D0 (en) 1997-08-27
ME00907B (me) 2007-08-03
ATE238812T1 (de) 2003-05-15
NO313125B1 (no) 2002-08-19
PE84899A1 (es) 1999-09-17
NZ501066A (en) 2001-01-26
JP5089004B2 (ja) 2012-12-05
EP1001813B8 (fr) 2014-02-12
CA2295035A1 (fr) 1998-12-30
IS5248A (is) 1999-11-15
MY118151A (en) 2004-09-30
OA11232A (en) 2003-05-26
TNSN98090A1 (fr) 2005-03-15
IS2004B (is) 2005-04-15
BR9809468A (pt) 2000-06-20
ES2195355T3 (es) 2003-12-01
NO995565L (no) 1999-11-30
CO4940450A1 (es) 2000-07-24
AP912A (en) 2001-12-08
KR100372988B1 (ko) 2003-02-25

Similar Documents

Publication Publication Date Title
DK1001813T3 (da) Farmaceutiske formuleringer indeholdende voriconazol
NO992339L (no) Farmasöytiske formuleringer
ID24654A (id) Formulasi farmasi omeprazola
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
BR9610153A (pt) Formulações farmacêuticas
BR9611626A (pt) Formulações farmacéuticas
NO20015670L (no) Forbedrede farmasöytiske formuleringer
DE59801987D1 (de) Pharmazeutische zusammensetzung enthaltend peptichemio
ID16781A (id) Formulasi-formulasi farmasi
DE69830154D1 (de) Pharmazeutische zusammensetzungen
ITMI941169A0 (it) Formulazioni farmaceutiche
ID30032A (id) Formulasi farmasi
ID25857A (id) Komposisi farmasi
ID23531A (id) Komposisi farmasi
DK1237551T3 (da) Farmaceutiske formuleringer indeholdende zolmitriptan
BR1100755A (pt) composição farmacêutica
ID21180A (id) Senyawa-senyawa farmasi
FI3862U1 (fi) Geelimuotoinen farmaseuttinen valmiste
SE9502453D0 (sv) Drug formulations
SE9404467D0 (sv) Drug formulations